Tom graduated University of Brighton with a BA (Hons) degree in Broadcast Journalism, leaving as the valedictorian of the class of 2015. His final year projects and dissertation were nominated for, and won, several awards, whilst he was also the Editor-in-Chief of the university’s news site during his time at Brighton. After previously writing for a property magazine, Tom joined the Proactive team in January 2016.
Indivior is still going through the courts to try to prove that Dr Reddy’s drug breaches its patents, but the lifting of the injunction means the Indian drugs giant can sell its version while a decision is made
Higher selling prices helped revenues edged higher, but profits fell by a third as a result of a rise in build costs, increased use of part-exchange and additional marketing activity
The upgrade came alongside half-year results, in which BTG reported a 12% in revenue and a 35% jump in adjusted operating profits
Over the past couple of weeks, the FTSE 100 drugs giant has sold off the rights to three asthma and hay fever treatments, one heartburn medicine, an arthritis drug and now a lung disease treatment
Data presented at a cancer convention in Dublin suggested SRA737 showed “promising efficacy” in pre-clinical models of high-grade serous ovarian cancer
Including the £6.1mln Series C investment, the value of Arix’s 11.3% stake in Harpoon has increased to £20.2mln
CRISPR will use MaxCyte’s Flow Electroporation technology to deliver its components into T-cells, which are known to attack the body’s own cells that have been infected by viruses
US firm Sierra Oncology, which is the licence holder of SRA737, said in its quarterly update, it has made “substantial progress” with its two clinical development programmes for the compound
Of course if you’ve already done so, this article probably doesn’t apply to you…
Sometimes a cheap stock is cheap for a reason, not just because it’s good value…
The Rookie Investors has still got the Fever(tree), but would he have done had he set a stop-loss?
As I venture into the world of equity trading, here’s the background to my story and where I’m at now